<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647192</url>
  </required_header>
  <id_info>
    <org_study_id>EPLERAF-01</org_study_id>
    <secondary_id>Version 09_D</secondary_id>
    <secondary_id>EudraCT number: 2007-002119-17</secondary_id>
    <nct_id>NCT00647192</nct_id>
  </id_info>
  <brief_title>EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion</brief_title>
  <acronym>EPLERAF</acronym>
  <official_title>EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Eplerenone reduces atrial fibrillation (AF)
      recurrences within the first 8 weeks after electrical cardioversion of persistent AF.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inclusion rate too low. Recruitment of further study centers too costly.
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation recurrence after electrical cardioversion of atrial fibrillation</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sinus rhythm within eplerenone treatment before planned electrical cardioversion</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardioversion success</measure>
    <time_frame>at least one sinus beat</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of atrial fibrillation</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eplerenone treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>50 mg per day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg per day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent atrial fibrillation (AF), AF persistence for &gt; 7 days but &lt; 1 year

          -  Total AF history &lt; 2 years

          -  Written informed consent of the patient

          -  Age ≥18 years

          -  Female patients are sterilised or postmenopausal or apply an adequate method for
             contraception (Pearl index &lt;1%) and have a negative pregnancy test (ß-HCG) and do not
             breastfeed/nurse.

        Exclusion Criteria:

          -  Hemodynamic instability or symptoms not allowing cardioversion to be delayed for 3
             weeks

          -  Myocardial infarction within the last 3 months

          -  Heart failure NYHA class III - IV

          -  Uncontrolled hypertension, defined as a systolic blood pressure &gt; 160 mm Hg and/or a
             diastolic blood pressure &gt; 95 mm Hg (anti-hypertensive treatment is allowed).

          -  Pre-treatment with an aldosterone antagonist or other potassium sparing diuretics

          -  Instable angina pectoris

          -  Use of Digitalis

          -  Use of class I or class III antiarrhythmic drugs (must be stopped at least 5 half-life
             before)

          -  Contraindication or hypersensitivity to ß-blockers

          -  Open heart surgery within the last 3 months

          -  Pregnancy

          -  Acute and reversible illnesses

          -  Acute and chronic infection

          -  Alcohol or drug abuse or a severe progressive extracardiac disease

          -  Untreated manifest and latent hyper- or hypothyroidism or &lt; 3 months peripheral
             euthyroidism (normal fT3)

          -  Moderate to severe renal insufficiency (Creatinine clearance less than 50 ml/min)

          -  Patients with liver cirrhosis (Child-Pugh class C)

          -  Co-administration of strong CYP3A4 inhibitors (e.g. Itraconazole, Ketoconazole,
             Ritonavir, Nelfinavir, Clarithromycin, Telithromycin and Nephazodon)

          -  Hypersensitivity against Eplerenone and/or one of the other components of the tablet
             (see Fachinformation)

          -  Serum potassium &gt; 5 mmol/l

          -  Patients unlikely to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Böhm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijksuniversiteit Groningen, Universitair Medisch Centrum</name>
      <address>
        <city>Groningen</city>
        <zip>NL-9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>February 9, 2012</last_update_submitted>
  <last_update_submitted_qc>February 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>electrical cardioversion</keyword>
  <keyword>prevention of atrial fibrillation recurrence</keyword>
  <keyword>mineralocorticoid receptor blocker</keyword>
  <keyword>eplerenone</keyword>
  <keyword>Recurrence of atrial fibrillation after cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

